One preclinical study using melanoma cancer cell lines WM-266-4 and B16F10 recently showed that serotonin type-3 (5-HT3) receptor antagonists, such as tropisetron and ondansetron, demonstrated a selective concentration-dependent toxic effect on melanoma cells through inhibition of NF-κB localization in the nuclei [49]. The gene discussed is NFKB1; the disease is melanoma.